secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001104659-25-048579
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quoin Pharma Q1 net loss $3.8M; positive QRX003 data and patent expansion
-------------------------------------------------------------------------

- Cash of $11.6M at March 31, 2025; expected to fund operations into Q1 2026.
- Net loss of $3.8M for Q1 2025, versus $2.3M in Q1 2024.
- QRX003 showed reversal of clinical benefits upon discontinuation, confirming mechanism of action.
- Patent applications filed for topical rapamycin and novel QRX003 formulations, extending IP to 2045.
- FDA-cleared whole-body QRX003 study at Northwestern University for 8-12 Netherton patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465925048579/0001104659-25-048579-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465925048579/tm2515088d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-048579

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer